|
US6395888B1
(en)
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
US6346611B1
(en)
|
1990-06-11 |
2002-02-12 |
Gilead Sciences, Inc. |
High affinity TGfβ nucleic acid ligands and inhibitors
|
|
US6232071B1
(en)
*
|
1990-06-11 |
2001-05-15 |
Gilead Sciences, Inc. |
Tenascin-C nucleic acid ligands
|
|
US6762290B1
(en)
*
|
1999-07-29 |
2004-07-13 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
|
AU782620B2
(en)
*
|
1991-06-10 |
2005-08-11 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
RU2250911C2
(ru)
|
1999-07-14 |
2005-04-27 |
Элзэ Копэрейшн |
Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
|
|
AU2001296305B2
(en)
*
|
2000-09-26 |
2007-12-06 |
Duke University |
RNA aptamers and methods for identifying the same
|
|
ES2346640T4
(es)
*
|
2001-10-26 |
2011-04-26 |
Noxxon Pharma Ag |
Ácido l-nucleico modificado.
|
|
US20030171320A1
(en)
*
|
2001-11-09 |
2003-09-11 |
Guyer David R. |
Methods for treating ocular neovascular diseases
|
|
US7094410B2
(en)
*
|
2002-03-02 |
2006-08-22 |
The Scripps Research Institute |
DNA vaccine against proliferating endothelial cells and methods of use thereof
|
|
US7767803B2
(en)
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
|
BR0313212A
(pt)
*
|
2002-07-24 |
2005-06-28 |
Hoffmann La Roche |
Aditivos de ácido de polialquileno glicol
|
|
EP1543158B1
(en)
|
2002-07-25 |
2011-07-13 |
Archemix Corp. |
Regulated aptamer therapeutics
|
|
US9303262B2
(en)
|
2002-09-17 |
2016-04-05 |
Archemix Llc |
Methods for identifying aptamer regulators
|
|
US8039443B2
(en)
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US10100316B2
(en)
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
US20040197804A1
(en)
*
|
2002-12-03 |
2004-10-07 |
Keefe Anthony D. |
Method for in vitro selection of 2'-substituted nucleic acids
|
|
RU2234097C1
(ru)
*
|
2003-03-05 |
2004-08-10 |
Московский областной научно-исследовательский клинический институт |
Способ диагностики саркомы капоши
|
|
FR2852606A1
(fr)
*
|
2003-03-18 |
2004-09-24 |
Inst Nat Sante Rech Med |
Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
|
|
EP2623601B1
(en)
|
2003-04-21 |
2015-02-18 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
CL2004001996A1
(es)
*
|
2003-08-08 |
2005-05-06 |
Eyetech Pharmaceuticals Inc |
Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
PL3385384T3
(pl)
|
2004-02-12 |
2021-03-08 |
Archemix Llc |
Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem
|
|
EP1737497A2
(en)
*
|
2004-04-13 |
2007-01-03 |
(Osi) Eyetech, Inc. |
Nucleic acid aptamers conjugated to high molecular weight steric groups
|
|
US7579450B2
(en)
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
|
EP1791557A4
(en)
|
2004-09-07 |
2009-09-23 |
Archemix Corp |
MEDICAL CHEMISTRY USING APTAMERS
|
|
US7566701B2
(en)
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
|
EP3034089A1
(en)
|
2004-11-02 |
2016-06-22 |
Archemix LLC |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
AU2006265896B2
(en)
|
2005-06-30 |
2012-05-31 |
Archemix Corp. |
Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
|
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
|
JP2009510182A
(ja)
*
|
2005-07-28 |
2009-03-12 |
（オーエスアイ）アイテツク・インコーポレーテツド |
シクリトールリンカーポリマー抱合体
|
|
CN101304748A
(zh)
|
2005-08-22 |
2008-11-12 |
加利福尼亚大学董事会 |
Tlr激动剂
|
|
KR100877824B1
(ko)
|
2005-11-11 |
2009-01-12 |
한국생명공학연구원 |
Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
|
|
BRPI0619463A2
(pt)
*
|
2005-12-06 |
2013-01-08 |
Domantis Ltd |
ligando, uso do mesmo, mÉtodos para tratar cÂncer e para administrar um tratamento anti-vegf e tratamento anti-egfr a um indivÍduo, composiÇço, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodo para produzir um ligando, polipeptÍdeo de domÍnio variÁvel simples de imunoglobulina, e, antagonista de egfr
|
|
AU2006325030B2
(en)
*
|
2005-12-16 |
2012-07-26 |
Cellectis |
Cell penetrating peptide conjugates for delivering nucleic acids into cells
|
|
WO2007080902A1
(ja)
*
|
2006-01-11 |
2007-07-19 |
Kyowa Hakko Kogyo Co., Ltd. |
眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤
|
|
HUE026496T2
(en)
|
2006-03-08 |
2016-06-28 |
Archemix Llc |
Complement-binding aptamers and anti-C5 agents for treating eye diseases
|
|
HUE025555T2
(en)
|
2007-02-07 |
2016-02-29 |
Univ California |
Conjugates and applications of synthetic tlr agonists
|
|
WO2009137095A2
(en)
|
2008-05-08 |
2009-11-12 |
The Johns Hopkins University |
Compositions and methods for modulating an immune response
|
|
CA2746003C
(en)
*
|
2008-12-04 |
2020-03-31 |
Opko Curna, Llc |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
|
CN102438978B
(zh)
|
2009-03-20 |
2017-02-22 |
Clsn实验室股份有限公司 |
聚胺衍生物
|
|
US20120295811A1
(en)
|
2009-11-23 |
2012-11-22 |
Jean-Jacques Toulme |
Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
EP2618846A1
(en)
*
|
2010-09-24 |
2013-07-31 |
Mallinckrodt LLC |
Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
|
|
WO2013153138A1
(en)
|
2012-04-11 |
2013-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
|
|
US10942184B2
(en)
|
2012-10-23 |
2021-03-09 |
Caris Science, Inc. |
Aptamers and uses thereof
|
|
EP2912182B1
(en)
|
2012-10-23 |
2021-12-08 |
Caris Science, Inc. |
Aptamers and uses thereof
|
|
WO2014100434A1
(en)
|
2012-12-19 |
2014-06-26 |
Caris Science, Inc. |
Compositions and methods for aptamer screening
|
|
CN105264072B
(zh)
|
2013-03-22 |
2019-05-10 |
国立大学法人东京大学 |
针对il-17的适体及其用途
|
|
MX2016000364A
(es)
|
2013-07-12 |
2016-05-09 |
Ophthotech Corp |
Metodos para tratar o prevenir afecciones oftalmologicas.
|
|
US20160319361A1
(en)
|
2013-08-28 |
2016-11-03 |
Caris Life Sciences Switzerland Holdings Gmbh |
Oligonucleotide probes and uses thereof
|
|
HRP20220066T1
(hr)
|
2014-12-11 |
2022-04-15 |
Bayer Healthcare Llc |
Liječenje makularne degeneracije povezane sa starenjem s malom aktivnom koroidnom neovaskularizacijskom lezijom
|
|
SG11201705312PA
(en)
|
2014-12-29 |
2017-07-28 |
Bonac Corp |
Composition containing nucleic acid molecule stably
|
|
WO2016145128A1
(en)
|
2015-03-09 |
2016-09-15 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
US10590425B2
(en)
|
2015-06-29 |
2020-03-17 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
|
US10941176B2
(en)
|
2015-07-28 |
2021-03-09 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
AU2017235661B2
(en)
|
2016-03-18 |
2023-06-08 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
|
US11293017B2
(en)
|
2016-05-25 |
2022-04-05 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
EP3332812A1
(en)
|
2016-12-07 |
2018-06-13 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Nucleic acid-based assembly and use of the assembly in cancer therapy
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
EP3650045B1
(en)
|
2017-07-04 |
2024-11-13 |
Daiichi Sankyo Company, Limited |
Drug for retinal degenerative disease associated with photoreceptor degeneration
|
|
WO2019210097A1
(en)
*
|
2018-04-25 |
2019-10-31 |
Vitrisa Therapeutics, Inc. |
Aptamers with stability, potency or half-life for enhanced safety and efficacy
|
|
GB202405551D0
(en)
|
2024-04-19 |
2024-06-05 |
Vvb Bio Pte Ltd |
Combination treatment
|